메뉴 건너뛰기




Volumn 12, Issue 2, 2014, Pages 220-228

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

Author keywords

Half life; Hemophilia; Hemostasis; Inhibitors; Pharmacokinetics

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A ALBUMIN FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

EID: 84893606658     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12477     Document Type: Article
Times cited : (37)

References (33)
  • 1
    • 84893594501 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Accessed July
    • Centers for Disease Control and Prevention. www.cdc.gov/ncbddd/hemophilia/data.html. Accessed July 2013.
    • (2013)
  • 3
    • 84893592106 scopus 로고    scopus 로고
    • World Federation of Hemophilia 2011. 4th edn. Accessed July
    • World Federation of Hemophilia 2011. Inhibitors in Hemophilia: A Primer. 4th edn. www1.wfh.org/publication/files/pdf-1122.pdf. Accessed July 2013
    • (2013) Inhibitors in Hemophilia: A Primer
  • 4
    • 84866863644 scopus 로고    scopus 로고
    • Immune tolerance in haemophilia: the long journey to the fork in the road
    • DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159: 123-34.
    • (2012) Br J Haematol , vol.159 , pp. 123-134
    • DiMichele, D.M.1
  • 5
    • 79955139784 scopus 로고    scopus 로고
    • A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B
    • Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-9.
    • (2011) Haemophilia , vol.17 , pp. 494-499
    • Recht, M.1    Pollmann, H.2    Tagliaferri, A.3    Musso, R.4    Janco, R.5    Neuman, W.R.6
  • 6
    • 35148857177 scopus 로고    scopus 로고
    • Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
    • Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
    • (2007) Vasc Health Risk Manag , vol.3 , pp. 527-531
    • Tjønnfjord, G.E.1    Holme, P.A.2
  • 7
    • 84893525238 scopus 로고    scopus 로고
    • ® SMPC. Accessed July
    • ® SMPC. www.medicines.org.uk/emc/medicine/21171/SPC/. Accessed July 2013
    • (2013)
  • 9
    • 53449102958 scopus 로고    scopus 로고
    • Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
    • Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122(Suppl. 4): S14-9.
    • (2008) Thromb Res , vol.122 , Issue.SUPPL. 4
    • Schulte, S.1
  • 11
    • 84866594053 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
    • Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
    • (2012) Blood , vol.120 , pp. 2405-2411
    • Santagostino, E.1    Negrier, C.2    Klamroth, R.3    Tiede, A.4    Pabinger-Fasching, I.5    Voigt, C.6    Jacobs, I.7    Morfini, M.8
  • 13
    • 37249082059 scopus 로고    scopus 로고
    • Overview of the human pharmacokinetics of recombinant activated factor VII
    • Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2007; 65: 3-11.
    • (2007) Br J Clin Pharmacol , vol.65 , pp. 3-11
    • Klitgaard, T.1    Nielsen, T.G.2
  • 15
    • 84860457217 scopus 로고    scopus 로고
    • Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
    • Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 2012; 10: 773-80.
    • (2012) J Thromb Haemost , vol.10 , pp. 773-780
    • Mahlangu, J.N.1    Coetzee, M.J.2    Laffan, M.3    Windyga, J.4    Yee, T.T.5    Schroeder, J.6    Haaning, J.7    Siegel, J.E.8    Lemm, G.9
  • 16
    • 0019191269 scopus 로고
    • The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits
    • Giles AR, Hoogendoorn H, Blajchman MA, Hirsh J. The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits. Thromb Res 1980; 17: 555-60.
    • (1980) Thromb Res , vol.17 , pp. 555-560
    • Giles, A.R.1    Hoogendoorn, H.2    Blajchman, M.A.3    Hirsh, J.4
  • 17
    • 79251554994 scopus 로고    scopus 로고
    • Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients
    • Agersø H, Brophy DF, Pelzer H, Martin EJ, Carr M, Hedner U, Ezban M. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011; 9: 333-8.
    • (2011) J Thromb Haemost , vol.9 , pp. 333-338
    • Agersø, H.1    Brophy, D.F.2    Pelzer, H.3    Martin, E.J.4    Carr, M.5    Hedner, U.6    Ezban, M.7
  • 18
    • 66149175575 scopus 로고    scopus 로고
    • Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors
    • Petersen LC, Elm T, Ezban M, Krogh TN, Karpf DM, Steinø A, Olsen EH, Sørensen BB. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-26.
    • (2009) Thromb Haemost , vol.101 , pp. 818-826
    • Petersen, L.C.1    Elm, T.2    Ezban, M.3    Krogh, T.N.4    Karpf, D.M.5    Steinø, A.6    Olsen, E.H.7    Sørensen, B.B.8
  • 20
    • 79955662245 scopus 로고    scopus 로고
    • GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa
    • Holmberg H, Elm T, Karpf D, Tranholm M, Bjørn SE, Stennicke H, Ezban M. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa. J Thromb Haemost 2011; 9: 1070-2.
    • (2011) J Thromb Haemost , vol.9 , pp. 1070-1072
    • Holmberg, H.1    Elm, T.2    Karpf, D.3    Tranholm, M.4    Bjørn, S.E.5    Stennicke, H.6    Ezban, M.7
  • 22
    • 0035160476 scopus 로고    scopus 로고
    • Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation
    • Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)
    • Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.
    • (2001) Thromb Haemost , vol.86 , pp. 1327-1330
    • Taylor Jr, F.B.1    Toh, C.H.2    Hoots, W.K.3    Wada, H.4    Levi, M.5
  • 23
    • 69249213501 scopus 로고    scopus 로고
    • Implementation of the ISTH classification of non-overt DIC in a thromboplastin induced rabbit model
    • Olrik Berthelsen L, Thuri Kristensen A, Wiinberg B, Tranholm M. Implementation of the ISTH classification of non-overt DIC in a thromboplastin induced rabbit model. Thromb Res 2009; 124: 490-7.
    • (2009) Thromb Res , vol.124 , pp. 490-497
    • Olrik Berthelsen, L.1    Thuri Kristensen, A.2    Wiinberg, B.3    Tranholm, M.4
  • 24
    • 84887557283 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers
    • Golor G, Bensen-Kennedy D, Haffner S, Easton R, Jung K, Moises T, Lawo JP, Joch C, Veldman A. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers. J Thromb Haemost 2013; 11: 1977-85.
    • (2013) J Thromb Haemost , vol.11 , pp. 1977-1985
    • Golor, G.1    Bensen-Kennedy, D.2    Haffner, S.3    Easton, R.4    Jung, K.5    Moises, T.6    Lawo, J.P.7    Joch, C.8    Veldman, A.9
  • 25
    • 0032465250 scopus 로고    scopus 로고
    • The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
    • Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9: 741-8.
    • (1998) Blood Coagul Fibrinolysis , vol.9 , pp. 741-748
    • Erhardtsen, E.1    Nony, P.2    Dechavanne, M.3    Ffrench, P.4    Boissel, J.P.5    Hedner, U.6
  • 27
    • 18944386159 scopus 로고    scopus 로고
    • A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects
    • Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16: 259-66.
    • (2005) Blood Coagul Fibrinolysis , vol.16 , pp. 259-266
    • Fridberg, M.J.1    Hedner, U.2    Roberts, H.R.3    Erhardtsen, E.4
  • 28
    • 55749111387 scopus 로고    scopus 로고
    • The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics
    • Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-83.
    • (2008) J Pharm Sci , vol.97 , pp. 4167-4183
    • Fishburn, C.S.1
  • 29
    • 0033654389 scopus 로고    scopus 로고
    • Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation
    • Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Sci 2000; 3: 125-36.
    • (2000) J Pharm Sci , vol.3 , pp. 125-136
    • Mehvar, R.1
  • 30
    • 79959828057 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects
    • Møss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011; 9: 1368-74.
    • (2011) J Thromb Haemost , vol.9 , pp. 1368-1374
    • Møss, J.1    Rosholm, A.2    Laurén, A.3
  • 31
    • 84893582243 scopus 로고    scopus 로고
    • Novo Nordisk press release. Accessed April
    • Novo Nordisk press release. www.novonordisk.com/images/investors/investor_presentations/2011/Q3/PR111027_9M_2011_UK.pdf. Accessed April 2013
    • (2013)
  • 32
    • 84893577086 scopus 로고    scopus 로고
    • Bayer press release. Accessed May
    • Bayer press release. www.investor.bayer.com/news/investor-news/investor-news/showNewsItem/1567/1367589360/98b78129e8/. Accessed May 2013
    • (2013)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.